Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

The New England journal of medicine - 23 Nov 2017

Taylor-Cousar Jennifer L, Munck Anne, McKone Edward F, van der Ent Cornelis K, Moeller Alexander, Simard Christopher, Wang Linda T, Ingenito Edward P, McKee Charlotte, Lu Yimeng, Lekstrom-Himes Julie, Elborn J Stuart

Abstract excerpt

BACKGROUND: Combination treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators tezacaftor (VX-661) and ivacaftor (VX-770) was designed to target the underlying cause of disease in patients with cystic fibrosis. METHODS: In this phase 3, randomized, double-blind, multicenter, placebo-controlled, parallel-group trial, we evaluated combination therapy with tezacaftor and ivacaftor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Combinations

Share to Forced Expiratory Volume

Share to Indoles

Share to Quality of Life

Share to Quinolones

Source

Identifiers

PMID: 29099344
DOI: 10.1056/NEJMoa1709846

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.PMID 29099344Read ↗

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.Semantic proximity Read ↗

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.Semantic proximity Read ↗

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesSemantic proximity Read ↗

Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.Semantic proximity Read ↗

Tezacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.Semantic proximity Read ↗

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.Semantic proximity Read ↗

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).Semantic proximity Read ↗

Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.Semantic proximity Read ↗

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.Semantic proximity Read ↗

Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.